Literature DB >> 11063727

Expression of mutant alpha-synuclein causes increased susceptibility to dopamine toxicity.

S J Tabrizi1, M Orth, J M Wilkinson, J W Taanman, T T Warner, J M Cooper, A H Schapira.   

Abstract

Mutations of the alpha-synuclein gene have been identified in autosomal dominant Parkinson's disease (PD). Transgenic mice overexpressing wild-type human alpha-synuclein develop motor impairments, intraneuronal inclusions and loss of dopaminergic terminals in the striatum. To study the mechanism of action through which mutant alpha-synuclein toxicity is mediated, we have generated stable, inducible cell models expressing wild-type or PD-associated mutant (G209A) alpha-synuclein in human-derived HEK293 cells. Increased expression of either wild-type or mutant alpha-synuclein resulted in the formation of cytoplasmic aggregates which were associated with the vesicular (including monoaminergic) compartment. Expression of mutant alpha-synuclein induced a significant increase in sensitivity to dopamine toxicity compared with the wild-type protein expression. These results provide an explanation for the preferential dopaminergic neuronal degeneration seen in both the PD G209A mutant alpha-synuclein families and suggest that similar mechanisms may underlie or contribute to cell death in sporadic PD.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11063727     DOI: 10.1093/hmg/9.18.2683

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  52 in total

1.  Expression of A53T mutant but not wild-type alpha-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death.

Authors:  L Stefanis; K E Larsen; H J Rideout; D Sulzer; L A Greene
Journal:  J Neurosci       Date:  2001-12-15       Impact factor: 6.167

Review 2.  Oxidative stress and nitration in neurodegeneration: cause, effect, or association?

Authors:  Harry Ischiropoulos; Joseph S Beckman
Journal:  J Clin Invest       Date:  2003-01       Impact factor: 14.808

3.  Synthesis of a Bis-thio-acetone (BTA) Analogue of the Lysine Isopeptide Bond and its Application to Investigate the Effects of Ubiquitination and SUMOylation on α-Synuclein Aggregation and Toxicity.

Authors:  Yuka E Lewis; Tharindumala Abeywardana; Yu Hsuan Lin; Ana Galesic; Matthew R Pratt
Journal:  ACS Chem Biol       Date:  2016-01-12       Impact factor: 5.100

4.  Protein aggregation in retinal cells and approaches to cell protection.

Authors:  Irina Surgucheva; Natalia Ninkina; Vladimir L Buchman; Kenneth Grasing; Andrei Surguchov
Journal:  Cell Mol Neurobiol       Date:  2005-09       Impact factor: 5.046

Review 5.  Molecular mechanisms of alpha-synuclein neurodegeneration.

Authors:  Elisa A Waxman; Benoit I Giasson
Journal:  Biochim Biophys Acta       Date:  2008-10-09

6.  Inhibition of vesicular monoamine transporter-2 activity in alpha-synuclein stably transfected SH-SY5Y cells.

Authors:  Jun Tang Guo; An Qi Chen; Qi Kong; Hua Zhu; Chun Mei Ma; Chuan Qin
Journal:  Cell Mol Neurobiol       Date:  2007-11-06       Impact factor: 5.046

Review 7.  Dopamine- or L-DOPA-induced neurotoxicity: the role of dopamine quinone formation and tyrosinase in a model of Parkinson's disease.

Authors:  Masato Asanuma; Ikuko Miyazaki; Norio Ogawa
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

8.  The H50Q mutation enhances α-synuclein aggregation, secretion, and toxicity.

Authors:  Ossama Khalaf; Bruno Fauvet; Abid Oueslati; Igor Dikiy; Anne-Laure Mahul-Mellier; Francesco Simone Ruggeri; Martial K Mbefo; Filip Vercruysse; Giovanni Dietler; Seung-Jae Lee; David Eliezer; Hilal A Lashuel
Journal:  J Biol Chem       Date:  2014-06-16       Impact factor: 5.157

Review 9.  Modulation of alpha-synuclein aggregation by dopamine: a review.

Authors:  Su Ling Leong; Roberto Cappai; Kevin Jeffrey Barnham; Chi Le Lan Pham
Journal:  Neurochem Res       Date:  2009-05-15       Impact factor: 3.996

Review 10.  Neurobiology of alpha-synuclein.

Authors:  Kostas Vekrellis; Hardy J Rideout; Leonidas Stefanis
Journal:  Mol Neurobiol       Date:  2004-08       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.